Mirati Therapeutics Doses First Patient in Expansion Cohorts of Phase 1b Trial of MGCD265 in Genetically Selected Patients
PR Newswire - Tue Dec 23, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl. In this segment of the study, one of the expansion cohorts will enroll patients with NSCLC and another will enroll patients with other solid tumors. Both cohorts will enroll only those patients that have specific MET driver mutations including MET gene point mutations, gene amplification, and MET or Axl gene rearrangements.
MRTX: 19.41 (+0.03)
Mirati Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 19, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 10:00 a.m. Eastern Time in New York.
MRTX: 19.41 (+0.03)
Mirati beats 3Q profit forecasts
Automated Insights - Mon Nov 10, 7:31AM CST
SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Monday reported a third-quarter loss of $8.6 million.
MRTX: 19.41 (+0.03)
Mirati Therapeutics beats by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:27AM CST
MRTX: 19.41 (+0.03)
Mirati Therapeutics Reports Third Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Mon Nov 10, 7:00AM CST
Mirati Therapeutics, Inc. ("Mirati"
MRTX: 19.41 (+0.03)
Michael Grey Joins Mirati Therapeutics Board of Directors
PR Newswire - Thu Nov 06, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran Michael Grey has joined its board of directors.
MRTX: 19.41 (+0.03)
Mirati Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference
PR Newswire - Wed Sep 10, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 10:30 a.m. Eastern Time in New York.
MRTX: 19.41 (+0.03)
Mirati Therapeutics Initiates Phase 1 Study of MGCD516 for Non-Small Cell Lung Cancer and Other Advanced Solid Tumors
PR Newswire - Thu Sep 04, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in its Phase 1 clinical study of MGCD516 in the treatment of patients with advanced solid tumors, with an initial focus on non-small cell lung cancer (NSCLC). MGCD516 is a Receptor Tyrosine Kinase (RTK) inhibitor with molecular targets that act as critical genetic drivers of cancer progression.
MRTX: 19.41 (+0.03)
Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma
PR Newswire - Mon Aug 11, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL). In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome (MDS). Orphan drug designation is also being sought for bladder cancer patients with specific genetic alterations.
MRTX: 19.41 (+0.03)
Mirati Therapeutics Reports Second Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Fri Aug 08, 7:00AM CDT
Mirati Therapeutics, Inc. ("Mirati"
MRTX: 19.41 (+0.03)
Mirati Therapeutics Added to Russell 2000 Index
PR Newswire - Mon Jun 30, 3:01PM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company has been added to the Russell 2000® Index following the annual reconstitution of its U.S. and global equity indexes on June 27, 2014.
MRTX: 19.41 (+0.03)
Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome
PR Newswire - Tue Jun 17, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration as a treatment for myelodysplastic syndrome (MDS). Mocetinostat is being developed in Phase 2 clinical studies in combination with Vidaza as a treatment for intermediate and high-risk MDS, as well as a single agent treatment in patients with diffuse large B-cell lymphoma (DLBCL) and bladder cancer targeting specific genetic mutations in histone acetylation that increase the likelihood of response in tumor cells.
MRTX: 19.41 (+0.03)
Mirati Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference
PR Newswire - Thu Jun 12, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 9:00 a.m. Eastern Time in New York.
MRTX: 19.41 (+0.03)